About MRC-Holland
MRC-Holland b.v. is a biotechnology company located in Amsterdam, the Netherlands. The company is a follow-up of Microbiology Research Centre Holland, founded in 1985 by Dr. Jan Schouten. Until 2000, the main products of MRC-Holland were restriction endonucleases -purified from a wide range of bacteria and blue green algae- and DNA molecular weight markers. These products were sold in bulk amounts to distributing companies worldwide.

In 1997, MRC-Holland started focusing on developing new techniques for DNA analysis. By far the most successful technique developed is Multiplex Ligation-dependent Probe Amplification, or MLPA®. The MLPA® technology was first described in Nucleic Acid Research 30, e57 (2002) by Schouten et al. Since then, hundreds of MLPA probe sets have been developed for a wide variety of genes and applications, some of which very rare.

At present, all activities of MRC-Holland are directed to the production of new MLPA-based products and the development of novel MLPA-based techniques. MRC-Holland currently has about 70 employees, working in development, quality testing, production, sales and customer service.

MRC-Holland office
new products
P472-SUFU
Familial Medulloblastoma and Meningioma
improved products
P101-STK11
Peutz-Jeghers syndrome (PJS)
P113-FANCB
Fanconi anemia complementation group B
P029-WBS
Williams-Beuren syndrome
P437-Familial MDS-AML
Familial MDS-AML
P210-BTK
Agammaglobulinemia
P373-Microdeletion-7
Microdeletion follow-up
Newsletter  |  Home  |  Site map  |  Terms and Conditions  |  Search  |  Copyright © 2017 MRC-Holland